慢性淋巴细胞白血病中的ATM异常:del(11q)而非ATM突变是不良预后生物标志物
在3631例未经治疗的慢性淋巴细胞白血病(CLL)患者中评估ATM异常(del(11q)和/或ATM突变)对至首次治疗时间(TTFT)的影响,并结合IGHV突变状态及9个CLL相关基因突变进行分析。ATM突变见于246例(6.8%),常与del(11q)共存(112/246例,45.5%)。多因素分析仅确定del(11q)、12三体、SF3B1和EGR2突变为Binet A期患者及M-CLL和U-CLL亚组中TTFT缩短的独立预后因素,ATM突变并非独立预后标志。
要点
- ATM突变见于246/3631例(6.8%),常与del(11q)共存(112/246例,45.5%)。
- 孤立ATM突变罕见,仅影响1.2%的Binet A期患者和<1%的M-CLL病例。
- 多因素分析仅del(11q)、12三体、SF3B1和EGR2突变为TTFT缩短的独立预后因素。
核心结论
- del(11q)而非ATM突变是CLL早期进展风险增加和治疗需求的关键生物标志物,尤其在惰性M-CLL中。
研究设计与样本
- 在3631例未经治疗的CLL患者中评估ATM异常(del(11q)和/或ATM突变)对TTFT的影响,并结合IGHV基因突变状态和9个CLL相关基因突变进行分析。
主要发现
- ATM突变见于246例(6.8%),常与del(11q)共存(112/246例,45.5%)。
- ATM突变患者的遗传异常谱因IGHV状态而异:M-CLL富集SF3B1和NFKBIE突变,U-CLL与12三体和TP53突变互斥。
- 孤立ATM突变罕见,影响1.2%的Binet A期患者和<1%的M-CLL病例。
- 单因素分析显示任何ATM异常的Binet A期患者TTFT较ATM野生型缩短,但多因素分析仅确定del(11q)、12三体、SF3B1和EGR2突变为Binet A期患者及M-CLL和U-CLL亚组中TTFT缩短的独立预后因素。
关键数值与推荐
- ATM突变频率:246/3631例(6.8%)。
- ATM突变与del(11q)共存:112/246例(45.5%)。
- 孤立ATM突变在Binet A期患者中占1.2%,在M-CLL病例中<1%。
- 多因素分析中TTFT缩短的独立预后因素:del(11q)、12三体、SF3B1突变、EGR2突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations were present in 246 cases (6.8%), frequently co-occurring with del(11q) (112/246 cases, 45.5%). ATM-mutated patients displayed a different spectrum of genetic abnormalities when comparing IGHV-mutated (M-CLL) and unmutated (U-CLL) cases: M-CLL was enriched for SF3B1 and NFKBIE mutations, whereas U-CLL showed mutual exclusivity with trisomy 12 and TP53 mutations. Isolated ATM mutations were rare, affecting 1.2% of Binet A patients and <1% of M-CLL cases. While univariable analysis revealed shorter TTFT for Binet A patients with any ATM aberration compared to ATM-wildtype, multivariable analysis identified only del(11q), trisomy 12, SF3B1, and EGR2 mutations as independent prognosticators of shorter TTFT among Binet A patients and within M-CLL and U-CLL subgroups. These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making.
引用
- Thorvaldsdottir B, Mansouri L, Sutton LA, et al. ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker. Leukemia. 2025. PMID: 40275070. doi:10.1038/s41375-025-02615-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。